Chardan Capital Reiterates “Buy” Rating for Oculis (NASDAQ:OCS)

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating reiterated by investment analysts at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $28.00 target price on the stock. Chardan Capital’s target price would suggest a potential upside of 49.73% from the company’s previous close.

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis has an average rating of “Buy” and a consensus price target of $28.80.

Oculis Stock Performance

Shares of Oculis stock opened at $18.70 on Tuesday. The company has a 50 day moving average price of $16.38 and a 200 day moving average price of $13.87. The firm has a market capitalization of $757.42 million, a P/E ratio of -9.69 and a beta of -0.33. Oculis has a 52 week low of $10.50 and a 52 week high of $18.72. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.